Estimates Revisions NewAmsterdam Pharma Company N.V. Deutsche Boerse AG
Stocks
KH6
NL00150012L7
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.88 EUR | +2.84% |
|
-1.16% | -15.32% |
| 08-06 | RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating | MT |
| 08-05 | NewAmsterdam Pharma Company N.V. - Analyst/Investor Day |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- NAMS Stock
- KH6 Stock
- Consensus NewAmsterdam Pharma Company N.V.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
